Amneal Pharmaceuticals, Inc.
AMRXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Amneal Pharmaceuticals, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in. The $5.94B market capitalization puts AMRX squarely in mid-cap range for its industry. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Market Cap
$5.94B
Beta
1.24
P/E (TTM)
35.52
P/E (Fwd)
14.69
EPS (TTM)
$0.48
EPS (Fwd)
$1.16
ROE
613.0%
ROA
8.6%
Cash
$131.4M
Total Debt
$2.79B
Free CF
-$115.3M
52W Change
77.6%
Annual Financials
Cash vs Debt
Where AMRX stands vs its 150-day and 200-day moving averages
As of the August 5, 2026 close, AMRX finished 29.96% above its 150-day moving average ($14.22) and 36.18% above its 200-day moving average ($13.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AMRX overbought or oversold?
At the August 5, 2026 close, AMRX's RSI(14) was 61.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, AMRX has $131.4M in cash with $2.79B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$115.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 613.0% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.21B (2022) to $3.02B (2025), reflecting a 36% increase over the period.
Amneal Pharmaceuticals, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AMRX.